# Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

> **NCT04223024** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 246 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** CCRT+Nimotuzumab
- **DRUG:** CCRT alone

## Key facts

- **NCT ID:** NCT04223024
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-31
- **Primary completion:** 2024-08-31
- **Final completion:** 2026-12
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223024, "Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04223024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*